ABSTRACT
INTRODUCTION: Anthracycline is a cornerstone in the treatment of various cancers. One major limitation to its use is cardiotoxicity. Renin angiotensin system (RAS) inhibitors have been shown to attenuate myocardial injury, initial data is promising in its use as prophylaxis for anthracyclineinduced cardiotoxicity. The aim of the study is to determine effectiveness of prophylactic RAS inhibitors in preventing anthracycline-induced cardiotoxicity and adverse cardiac events among adult cancer patients METHODS: Systematic search of databases PUBMED, MEDLINE, EMBASE, and CENTRAL was done. Selection criteria were: 1) randomized controlled trials (RCT) 2) adult cancer patients with normal ejection fraction and without heart failure symptoms 3) RAS inhibitors as prophylaxis versus placebo 4) development of cardiac events, all-cause mortality and left ventricular ejection fraction (LVEF) reduction as outcomes. Two reviewers independently assessed the trials. Disagreements were resolved with a third reviewer. Test for effect of intervention, heterogeneity, trial quality and risk of bias were assessed using the Cochrane Review Manager Software version 5.3. RESULTS: Five RCTs involving 530 adult patients, with average age of 50± two years old, and average follow-up from six months to three years were included. Combined clinical outcomes of heart failure, cardiac events and all-cause mortality showed an RR of 0.27[95%CI 0.18, 0.40],p CONCLUSION: Renin angiotensin system (RAS) inhibitors may be used as prophylaxis for cardiotoxicity. As prophylaxis, it reduced the clinical outcome of cardiac events, heart failure, and all-cause mortality among cancer patients needing anthracycline. Combined RAS inhibitor and betablocker limits LVEF reduction.
Subject(s)
Humans , Male , Female , Cardiotoxicity , Renin-Angiotensin System , MEDLINE , Stroke Volume , Patient Selection , Follow-Up Studies , Anthracyclines , PubMed , Heart Failure , Adrenergic beta-Antagonists , NeoplasmsABSTRACT
INTRODUCTION: Patients with acute coronary syndrome (ACS) exhibit a wide spectrum of early risk of death (one to 10 percent). High platelet counts may indicate a propensity for platelet-rich thrombi. Lymphocyte counts drop during ACS due to stress-induced cortisol release. Combining these two markers, recent studies have found that the platelet-tolymphocyte ratio (PLR) is associated with adverse cardiac events among patients with ACS, but local data is limited. The objective of this study is to determine if an elevated PLR taken on admission is associated with higher rates of adverse cardiac events. METHODS: A retrospective cohort of adult patients with ACS admitted at the UP-Philippine General Hospital was analyzed. Leukocyte and platelet counts were measured by an automated hematology analyzer. The PLR values of these patients were computed, and they were stratified into two groups after determining the optimal cut-off from the receiver operating characteristic curve (ROC) curve. The primary outcome was in-hospital mortality. Secondary outcomes included development of heart failure, cardiogenic shock, reinfarction, and significant arrhythmias. RESULTS: A total of 174 Filipinos with ACS were included. In-hospital mortality occurred in 30 patients (17%). These patients had a higher PLR compared to those who were discharged alive (p-value CONCLUSION: Among Filipino patients with ACS, an elevated PLR taken within 24 hours of admission is a useful marker to predict in-hospital mortality, thus providing vital information for risk stratification and more aggressive management strategies.
Subject(s)
Humans , Male , Female , Middle Aged , Adult , Blood Platelets , Acute Coronary Syndrome , Shock, Cardiogenic , Hospital Mortality , Hydrocortisone , Hospitals, General , Philippines , Lymphocyte Count , Heart Failure , Arrhythmias, Cardiac , Leukocytes , HematologyABSTRACT
INTRODUCTION: Cardiac hemangiomas are rare benign primary tumors.We present the successful management of a patient with a hemangioma causing significant right ventricular outflow tract (RVOT) obstruction.CLINICAL PRESENTATION: A 54-year-old female with no co-morbidities presented with progressive right-sided heart failure symptoms.Examination revealed a prominent right ventricular heave, irregular cardiac rhythm,murmurs consistent with pulmonic stenosis and tricuspid regurgitation, ascites, and bipedal edema. Given the echo features of the mass and the patient's clinical course,we favored a benign cardiac tumor over malignancy.Differentials included myxoma, fibroma, and papillary fibroelastoma. Medical management included enoxaparin and carvedilol as anticoagulation and rate control for the atrial flutter, respectively. Surgical treatment consisted of tumor excision and tricuspid valve annuloplasty.RESULTS: Intra-operatively, the stalk was indeed attached to the RV free wall. Histopathology was consistent with primary cardiac hemangioma. The patient's post-operative course was complicated by pneumonia, acute kidney injury, and tracheostomy, but she was eventually discharged improved after a month in the ICU.SIGNIFICANCE: This report highlights a rare primary cardiac tumor in an unusual location. While there have been several reports in the world literature on cardiac hemangiomas, less than ten cases have been shown to have significant RVOT obstruction as in our patient.CONCLUSION: Cardiac hemangiomas should be part of the differential diagnosis for an intracardiac mass in the right ventricle. Meticulous echocardiography can be a non-invasive and inexpensive aid to diagnosis and pre-operative planning.
Subject(s)
Humans , Female , Middle Aged , Tricuspid Valve , Carvedilol , Enoxaparin , Tricuspid Valve Insufficiency , Heart Ventricles , Tracheostomy , Myxoma , Heart Neoplasms , Propanolamines , Hemangioma , Pulmonary Valve StenosisABSTRACT
BACKGROUND: Polyangiitis overlap syndrome (POS),a systemic vasculitis not classifiable into well-defined syndromes, is diagnosed based on combined characteristics of two or more primary systemic vasculitides, such as Takayasu arteritis and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but not two AAVs. Our objective is to present such, with associated multiple infections.CASE: A 25-year-old Filipino female had six years of recurrent purpura, debilitating joint pains, hemoptysis, rhinorrhea, epistaxis, eye redness, dyspnea, and abdominal cramps. She was cachectic, had oral ulcers, bibasal crackles, polyarthritis, and generalized purpura. Work-up showed anemia, eosinophilia excluding parasitism, elevated inflammatory markers, and positive cytoplasmic (c)-ANCA and anti-proteinase 3. There was chronic sinusitis on rigid rhinoscopy, middle to lower lung field interstitial infiltrates on radiographs, pulmonary vasculitis on chest CT, moderate pulmonary hypertension on echocardiography, but normal spirometry. Skin biopsy showed leukocytoclastic vasculitis without necrotizing granulomas.Serology showed chronic hepatitis B infection. Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus grew from bronchial washings and nasal swabs, respectively. ASO titer was high. Human immunodeficiency virus infection was ruled out. She was diagnosed with POS,with features of two AAVs- limited granulomatosis with polyangiitis (GPA) and Churg-Strauss syndrome (CSS), associated with multiple infections, and was given naproxen and culture-guided antibiotics (ciprofloxacin, clindamycin, penicillin),with partial resolution of symptoms. Prednisone 10 mg once a day (OD) was started two weeks after hepatitis B reactivation prophylaxis with lamivudine 100mg OD. Complete resolution of skin lesions and upper airway symptoms and inflammatory marker improvement were observed after 12 weeks. She is maintained on prednisone 5.0 mg daily.CONCLUSION AND RECOMMENDATIONS: This is the first reported case of POS involving two AAVs - limited GPA and incomplete CSS, associated with multiple pathogens.Identifying POS is important; inability to classify patients into well-recognized vasculitic syndromes delays treatment. The infections likely perpetuated the vasculitis, and both antimicrobials and immunosuppression were necessary to induce disease remission